Memantina Aluzime (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist of the NMDA receptor. By blocking excessive calcium entry through the receptor‑associated ion channel, it reduces excitotoxic neuronal damage while allowing normal synaptic transmission, which can slow the progression of cognitive decline in Alzheimer’s disease.

The specific dose of Memantina Aluzime is determined by the prescribing clinician based on the patient’s condition, age, renal function and other factors. Dosage titration follows established clinical guidelines, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

The safety of memantine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as cholinesterase inhibitors (donepezil, rivastigmine) work by enhancing acetylcholine signaling. Memantine is often used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit.

Memantina Aluzime should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually once daily after a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, can include severe skin reactions such as Stevens‑Johnson syndrome, seizures, hallucinations or psychosis, cardiac arrhythmias, hepatic dysfunction and suicidal thoughts. Patients should seek immediate medical attention if any of these symptoms develop.

Memantina Aluzime is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any of the tablet excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists, unless a specialist determines it is appropriate.